The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients’ access to the treatments will be.

**How ICER’s Missteps Leave Access in Doubt For Atopic Dermatitis Patients**

The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients’ access to the treatments will be.

---

**Misstep #1**

**Calculate Treatment’s Value Based on Non-existent Price**

*Report determines cost effectiveness before one therapy is even priced and available.*

**Misstep #2**

**Undervalue Health Benefit without Long-term Data**

*Report evaluates effectiveness though long-term impact data doesn’t yet exist – then uses the lack of data to justify reducing the net health benefit from a “B+” to a “C+”*.

**Misstep #3**

**Overlook Crucial Patient Factors**

*Report fails to incorporate quality-of-life benefits that matter to patients.*

**Misstep #4**

**Leave Access Subject to Tentative & Incomplete Information**

*Report bases analysis on incomplete data, offering tentative findings that may not supply the consistent, long-term access patients need.*

---

**Do ICER’s findings promise patient access?**

**Or set patients up for challenges to come?**